CRISPR-Cas9 mediated genome editing ofLamin A (as confirmed by next generation sequencing) was achieved by using LentiArray™ Lentiviral sgRNA (Product # A32042, AssayID CRISPR817702_LV) and LentiArray Cas9 Lentivirus (Product # A32064). Fig (a) Western blot analysis of Lamin A was performed by loading 30 µg of HeLa Cas9 (Lane 1) and HeLa Cas9 cells transduced with Lamin A Lentiviral sgRNA (Lane 2) modified whole cell extracts. The samples were electrophoresed using NuPAGE™ Novex™ 4-12% Bis-Tris Protein Gel (Product # NP0322BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with Anti-Lamin A Monoclonal Antibody (4A4-A4), eBioscience™ (Product # 14-9848-82) using 0.2 µg/mL dilution and Goat anti-Mouse IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A28177 1:10000 dilution).Chemiluminescent detection was performed using SuperSignal™ West Dura Extended Duration Substrate (Product # 34076). A loss of signal in sgRNA transduced cells using the LentiArray™ CRISPR product line confirms that antibody is specific toLamin A (Fig (b)).